10.12.2014
  • DEINOVE has been granted five new patents this year, including its first in China

  • These patents protect the technological basis of the DEINOL process: degradation of lignocellulosic biomass and bioethanol production by Deinococcus

Montpellier, December 10, 2014 – DEINOVE (Alternext Paris: ALDEI), a cleantech company that designs and develops new industrial production standards based on the exploitation of Deinococcus bacteria, announces today the issuance of its first patent in China: the PF4 patent “Compositions and methods for degrading lignocellulosic biomass” .

Other four patents were issued to DEINOVE in 2014: the PF2 patent in Eurasia “Use of bacteria for the production of bioenergy” , the PF6 patent in Ukraine “Recombinant bacteria and the uses thereof for producing ethanol” , and the PF8  and PF9  patents in South Africa related to the digestive enzymes of plant polymers. All these patents cover the basis of the DEINOL process in the production of 2G bioethanol.

The Company has built a unique portfolio of patents and innovative industrial bioprocesses based on Deinococcus bacteria. Today, it owns 183 international patent applications divided into 16 patent families including methods for microbial selection and identification, Deinococcus genetic engineering techniques, its unique capabilities, such as hydrolysing the lignocellulosic biomass, and its diverse industrial applications including the production of bioethanol and other bio-based compounds.

"We welcome the granting of these new patents addressing the degradation of the 2G biomass, and especially the patent issued in China. They help increase very significantly our panel of patents and geographical coverage. Intellectual property is obviously a major element of value creation in our markets", states Emmanuel Petiot, CEO of DEINOVE. He recalls that "Unlike the microorganisms commonly used, Deinococcus offers a substantial range of opportunities to develop. Therefore, we have the considerable advantage of building global, exclusive, proprietary technology that will allow us to deliver high-performance bioproduction systems, economically viable and environmentally much more efficient."